NCT06401642View on ClinicalTrials.gov

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 22, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Migraine
Interventions
DRUG

Zavegepant

10 mg intranasal

Trial Locations (1)

85254

RECRUITING

Mayo Clinic in Arizona, Phoenix

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06401642 - Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications | Biotech Hunter | Biotech Hunter